ClinicalTrials.gg
CompletedNCT01192880Updated Feb 15, 2017

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

A Phase 3 interventional study of Placebo and Bitopertin in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 103 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-15.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
625
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
2nd of 16
625 · median 294
Started
2010
with 5 others
Phase 3
6 of 19
none open now
Registered
3rd of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2010, is one of 6 in phase 3, and was the 3rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of schizophrenia. Participants, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Based on the screening Structured Clinical Interview for and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) - Clinical Trial (SCID CT), a - Text Revision (DSM-IV-TR) diagnosis of schizophrenia, paranoid, disorganized, residual, undifferentiated or catatonic subtype
  • A score of 40 or greater on the sum of the 14 PANSS negative and disorganized thought factor items (items scored 1-7 for a maximum possible score of 98)
  • A score of 22 or less on the sum of the 8 PANSS positive symptom factor items. The score of the items of P1 (delusions), P3 (hallucinatory behavior), P6 (suspiciousness) and G9 (unusual thought content) meet the following requirements: no more than 2 of the above items have a score of 4; all of the above items score less than 5
  • Clinical stability for 6 months prior to randomization as well as antipsychotic treatment stability for the past 8 weeks at the time of randomization
  • Are at least moderately ill, as defined by Clinical Global Impression - Severity (CGI S) of negative symptoms score more than or equal to (>/=) 4
  • Stable doses of anticholinergic, antidepressive medication for at least 8 weeks prior to randomization is allowed as long as the respective scales cut-off entry criteria are met
  • With the exception of clozapine, participants are on any of the available marketed atypical or typical antipsychotics (treatment with a maximum of 2 antipsychotics)
  • Have a caregiver considered reliable by the investigator
  • Female participants who are not either surgically sterile or must agree to use at least one effective forms of from agree to remain sexually abstinent from screening until 90 days after the completion of the study medication

Exclusion criteria

Exclusion Criteria:

  • Evidence that participant has , uncontrolled and unstable disorder (for example, cardiovascular, renal, hepatic disorder)
  • (BMI) of less than (\<) 17 or more than (>) 40 kilograms per meter square (kg/m\^2)
  • Depressive symptoms, defined as a score of 9 or greater on the Calgary Depression Rating Scale for Schizophrenia (CDSS)
  • A severity score of >/=3 on the Parkinsonism item of the Extrapyramidal Symptoms Rating Scale - Abbreviated (ESRS-A) (Clinical Global Impression, Parkinsonism)
  • Positive result on the serum pregnancy test or are breast feeding at screening, or intend to become pregnant during the course of the trial.
  • History of neuroleptic malignant syndrome (NMS)
  • Based on the criteria and screening SCID-CT have: other current DSM-IV-TR Axis I diagnosis; alcohol or substance dependence within 12 months or abuse within 3 months with the exception of nicotine; dementia, delirium and other amnestic disorder per DSM-IV-TR
  • Treated with electroconvulsive therapy (ECT) within 6 months prior to randomization
  • Ever received RO4917838 or another glycine transporter 1 (GLYT 1) inhibitor
  • Require high doses of benzodiazepines (> 4 mg per day lorazepam or equivalent)
  • Have a positive urine drug screen for amphetamines (including 3,4-Methylenedioxymethamphetamine [MDMA]/ecstasy), cocaine, barbiturate, cannabis and/or opiates
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
625 participants (actual)

Study arms

  • Experimental
    Bitopertin 10 mg + Antipsychotics

    Treatment Period 1: Participants will receive bitopertin 10 milligrams (mg) tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 10 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50 percent (%) of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.

    Drug: Bitopertin · Drug: Antipsychotics

  • Experimental
    Bitopertin 20 mg + Antipsychotics

    Treatment Period 1: Participants will receive bitopertin 20 mg tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 20 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50% of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 20 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.

    Drug: Bitopertin · Drug: Antipsychotics

  • Placebo comparator
    Placebo

    Treatment Period 1: Participants will receive bitopertin matching placebo tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin matching placebo tablet orally once daily for 32 weeks (up to Study Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and will be switched to (in blinded manner) bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.

    Drug: Placebo · Drug: Antipsychotics

Interventions

  • DrugPlacebo

    Participants will receive bitopertin matching placebo once daily for 56 weeks.

  • Participants will receive 10 mg or 20 mg of bitopertin.

    Also known as: RO4917838

  • Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Negative Symptom Factor Score at Week 24

    Time frame: Baseline, Week 24

  2. Percentage of Participants with Adverse Events

    Time frame: From baseline up to 24 weeks

Secondary outcomes

  1. Mean Change from Baseline in the Personal and Social Performance (PSP) Total Score at Week 24

    Time frame: Baseline, Week 24

  2. Mean Change from Baseline in the PANSS Total Score at Week 24

    Time frame: Baseline, Week 24

  3. Mean Change from Baseline in the PANSS Factor Scores at Week 24

    Time frame: Baseline, Week 24

  4. Mean Change from Baseline in the PANSS Subscale Scores at Week 24

    Time frame: Baseline, Week 24

  5. Percentage of Participants With Response, as Assessed by PANSS Negative Symptom Factor Score

    Time frame: Week 24

  6. Percentage of Participants with Response, as Assessed by CGI-I Overall and Negative Symptoms Rating Score

    Time frame: Week 24

  7. Percentage of Participants with Both At Least 20% Improvement from Baseline in the PANSS Negative Symptom Factor Score and with a CGI-I Negative Symptoms Rating of Either Much or Very Much Improvement

    Time frame: Week 24

  8. Mean Change from Baseline in the CGI-S Overall and Negative Symptoms Rating Score

    Time frame: Baseline, Week 24

07

Study locations

103 sites
  • Clinical Innovtions Inc
    Costa Mesa, California 92626, United States
  • Synergy Clinical Research of Escondido
    Escondido, California 92025, United States
  • San Fernando Mental Health Center
    Granada Hills, California 91344, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • Excell Research
    Oceanside, California 92056, United States
  • Artemis Institute for Clinical Research, LLC
    San Diego, California 92103, United States
  • Collaborative Neuroscience Network Inc.
    Torrance, California 90502, United States
  • Behavioral Clinical Research Inc.
    Lauderhill, Florida 33319, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 3273, United States
  • Berma Research Group
    Plantation, Florida 33317, United States
  • Atlanta Center For Medical Research
    Atlanta, Georgia 30308, United States
  • Indiana University; LaRue Carter Memorial Hospital-Research Unit
    Indianapolis, Indiana 46222, United States
  • Clinical Insights, Inc.
    Glen Burnie, Maryland 21061, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Ocean Rheumatology
    Toms River, New Jersey 08775, United States
  • State University of New York at Buffalo; Department of Psychiatry
    Buffalo, New York 14215, United States
  • New York State Psychiatric Institute; Psychiatry Dept of Columbia University
    New York, New York 10032, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Keystone Clinical Studies, LLC
    Norristown, Pennsylvania 19403, United States
  • Scranton Medical Institutes Llc.
    Scranton, Pennsylvania 18503, United States
  • Community Clinical Research Inc.
    Austin, Texas 78754, United States
  • University Hills Clinical Research
    Irving, Texas 75062, United States
  • Lifetree Clinical Research
    Salt Lake City, Utah 84106, United States
  • Eastside Therapeutic Resource
    Kirkland, Washington 98033, United States
  • DDPDS Prof Dr Ivan Temkov EOOD
    Bourgas, 8000, Bulgaria
  • MHAT Dr.Hristo Stambolski EOOD; Psychiatry Ward of Acute Psychotic Disiorders in Severe Stage
    Kazanlak, 6100, Bulgaria
  • State Psychiatric Hospital Sv. Ivan Rilski Novi Iskar; First Man Dept. and First Woman Dept.
    Novi Iskar, 1282, Bulgaria
  • State Psychiatric Hospital - Pazardzhik AD; Department for active treatment of men and for women
    Pazardzhik, 4400, Bulgaria
  • UMHAT Dr Georgi Stranski; EAD; Psychiatry
    Plovdiv, 4002, Bulgaria
  • State Psychiatric Hospital Dr. G. Kissiov; 3-d Women Ward 1-st Men Ward
    Radnevo, 6260, Bulgaria
  • DDPDIU-Ruse; Men acute department Women acute department
    Rousse, 7003, Bulgaria
  • Military Medical Academy- MHAT
    Sofia, 1606, Bulgaria
  • Hebei Mental Health Centre
    Baoding, 071000, China
  • Beijing Huilongguan Hospital; Department of Psychiatric
    Beijing, 071000, China
  • Peking University Sixth Hospital; Department of Psychiatry
    Beijing, 100083, China
  • Beijing An Ding Hosp.Capital Medical University; 5th Clinical Dept Depression Centre
    Beijing, 100088, China
  • The Second Xiangya Hospital of Central South University
    Changsha, 410011, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • Guangzhou Brain Hospital
    GuangzhouGuangdong, 510370, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University(First Hospital of Zhejiang
    Hangzhou, 310003, China
  • The Second Affiliated Hospital of Zhejiang University College
    Hangzhou, 310009, China
  • The First Affilliated Hospital of Kunming Medical College
    Kunming, 650032, China
  • Nanjing Brain Hospital
    Nanjing, 210029, China
  • Shanghai Mental Health Center
    Shanghai, 200030, China
  • Tongji Hospital of Tongji University
    Shanghai, 200065, China
  • Renmin Hospital of Wuhan University
    Wuhan, 430060, China
  • Wuxi Mental Health Center
    Wuxi, 214151, China
  • The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital)
    Xi'an, 710032, China
  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
    Xi'an, 710061, China
  • Xi'an Mental Health Center
    Xi'an, 710061, China
  • Saint Anne s.r.o.
    Brno, 602 00, Czech Republic
  • Krajska nemocnice Liberec a.s.
    Liberec, 460 63, Czech Republic
  • Psychiatricka ambulance
    Melnik, 276 01, Czech Republic
  • A-Shine s.r.o.
    Plzen, 312 00, Czech Republic
  • Clintrial,s.r.o.
    Praha 10, 100 00, Czech Republic
  • Medical Services Prague s.r.o.
    Praha 6, 160 00, Czech Republic
  • Psychiatricke Centrum Praha
    Praha 8 - Bohnice, 181 03, Czech Republic
  • CTCenter MaVe s.r.o.
    Sternberk, 785 01, Czech Republic
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, Campania 80131, Italy
  • Asst Degli Spedali Civili Di Brescia; Servizio di farmacia
    Brescia, Lombardia 25123, Italy
  • Clinica Mangiagalli
    Milano, Lombardia 20122, Italy
  • ASST FATEBENEFRATELLI SACCO; Psichiatria (Fatebenefratelli)
    Milano, Lombardia 20124, Italy
  • Azienda Ospedaliero Universitaria Molinette San Giovanni Bat
    Torino, Piemonte 10126, Italy
  • Azienda Ospedaliero-Universitaria Consorziale Pol. di Bari; Neuroscienze e Organi di Senso
    Bari, Puglia 70124, Italy
  • A.O. Universitaria Pisana; Psichiatria
    Pisa, Toscana 56126, Italy
  • Azienda Ospedaliera di Padova
    Padova, Veneto 35128, Italy
  • Kohnodai Hp., National Center for Global Health and Medicine
    Chiba, 272-8516, Japan
  • Fukkokai Soubu Hospital
    Funabashi-shi, 273-8540, Japan
  • Daiwakai Seimou Hospital
    Gunma, 370-2455, Japan
  • Koseikai Kusatsu Hospital
    Hiroshima-shi, 733-0864, Japan
  • Hokkaido University Hospital
    Hokkaido, 060-8648, Japan
  • NHO Hizen Psychiatric Medical Center
    Kanzaki-gun, 842-0192, Japan
  • Sankeikai Nishigahara Hospital
    Kita-Ku, 114-0024, Japan
  • Hospital of the University of Occupational and Environmental Health,Japan
    Kitakyushu-shi, 807-8556, Japan
  • Jinseikai Hosogi Unity Hospital
    Kochi-shi, 780-8535, Japan
  • NHO Kikuchi National Hospital
    Koshi-shi, 861-1116, Japan
  • Yuge Hospital
    Kumamoto-shi, 861-8002, Japan
  • Jinkokai Kurayoshi Hospital
    Kurayoshi-shi, 682-0023, Japan
  • NHO Higashiowari Hospital
    Nagoya-Shi, 463-0802, Japan
  • Shinkokai Shiranui Hospital
    Omuta-shi, 836-0004, Japan
  • Asakayama General Hospital
    Sakai-shi, 590-0018, Japan
  • Tonankai Ashirbetsu Hospital
    Sapporo-shi, 004-0841, Japan
  • Sawayamakai Teine Hospital
    Sapporo-shi, 006-0816, Japan
  • Tohoku Seishin Hokenkai Aoba Hospital
    Sendai-shi, 983-0836, Japan
  • Jisenkai Nanko Psychiatric Institute
    Shirakawa-shi, 961-0021, Japan
  • Tokyo Women's Medical University Hospital
    Tokyo, 162-8666, Japan
  • National Center Of Neurology And Psychiatry Hospital
    Tokyo, 187-8551, Japan
  • Korenkai Minamitoyama Nakagawa Hospital
    Toyama-shi, 939-8073, Japan
  • Fujita Health University Hospital
    Toyoake-shi, 470-1192, Japan
  • Deep Intention Hiyoshi Hospital
    Yokohama-shi, 223-0062, Japan
  • Kanagawa Prefectural Psychiatric Center Kinko Hospital
    Yokohama-shi, 233-0006, Japan
  • Yokohama Aihara Hospital
    Yokohama-shi, 246-0026, Japan
  • Kemerovo Regional Clinical Psychiatric Hospital
    Kemerovo, 650036, Russian Federation
  • GUZ Lipetsk Regional psychoneurological Hospital #1; Dispansary Department
    Lipetsk, 399313, Russian Federation
  • Institution of RAMS (Mental Health Research Center of RAMS); Psychopharmacology laboratory
    Moscow, 115522, Russian Federation
  • Central Moscow Regional Clinical Psychiatric Hospital
    Moscow, 127083, Russian Federation
  • MHI City Clinical Hospital #2 named after V.I. Razumovsky; Psychiatric
    Sartatov, 410028, Russian Federation

Showing the first 100 of 103 sites across 7 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017 Dec;190:172-179. doi: 10.1016/j.schres.2017.03.040. Epub 2017 Apr 20. PubMed 28433500 ↗
  • Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Biol Psychiatry. 2017 Jul 1;82(1):8-16. doi: 10.1016/j.biopsych.2016.11.014. Epub 2016 Dec 15. PubMed 28117049 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Sep 1, 2010
Start
Nov 2010
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results delay requested
Jun 30, 2016
Last update
Feb 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01192880
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 1, 2010
Start date
Nov 2010
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Feb 15, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion